|From the President's Desk:
The World Heart Federation (WHF) 2nd Global Summit on Circulatory Health was held in Singapore, July 12-13, 2017, and we are very pleased that the IAS Federation Chair of the Asia-Pacific Region, Shizuya Yamashita, was invited to speak in the workshop on access to essential and affordable medicines and technologies as the representative of the International Atherosclerosis Society (IAS).
Prof. Yamashita joined over 100 leaders of global, regional, and national organizations which met to discuss how to create the case for urgent action in the fight against circulatory diseases. The overall objective was to build on the United Nations goal of a 25% reduction in premature non-communicable disease mortality by 2025, Goal 3 of the Sustainable Development Goals (SDGs), and in anticipation of the forthcoming United Nations High-Level Meeting on Noncommunicable Diseases (UN HLM on NCDs) in September 2018.
David Wood, President of the World Heart Federation, stated, "Without swift adoption of prevention and intervention strategies, current worldwide trends indicate increased global death and disability from preventable circulatory diseases. The global health community must act now with a greater sense of urgency if we are to contend with the world’s number one killer.”
Through a series of workshops, panel discussions, and plenary sessions moderated by Richard Horton from The Lancet, a consensus was rapidly reached on the need to collectively support the implementation of the 25 by 25 agenda at both the national and global level through the following actions:
Also included in this Newsletter:
Novel Proteomic Approaches to Identify Circulating Cardiovascular Biomarkers
By: José Tuñón, Luis Blanco-Colio, Óscar Lorenzo, Jesús Egido, and José Luis Martín-Ventura
Atherothrombosis is among the leading causes of mortality and disability in the world. Although new therapies have been developed in the last years, our patients continue to have cardiovascular events, suggesting that we need new therapeutic targets. However, there is an additional issue: our patients do not share a similar evolution. While some of them may experience recurrent cardiovascular events, other may have an isolated acute event followed by long periods of clinical stability. Thus, it follows that it would be ideal to identify patients at high risk of progression of the disease in order to concentrate on them the most intensive therapies.
Circulating biomarkers may be helpful identifying high-risk patients, given that blood is permanently exchanging molecules with the vascular wall and then it can provide us with information about vascular biology.
> View Complete Commentary <
Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease
By: Andreas Kousios, Panayiotis Kouis, and Andrie G Panayiotou
Cardiovascular disease (CVD) is the leading cause of death in end-stage renal disease patients (ESRD). Chronic kidney disease (CKD), even from its early asymptomatic stages and proteinuria, increases the risk for CVD substantially. Traditional CVD risk factors are highly prevalent in CKD patients; however, the use of traditional risk factor scores underestimates the CVD risk in patients with CKD.
Subclinical Atherosclerosis and the Pathophysiologic Role of MMPs in CKD
The atherosclerotic changes of the arterial wall that precede CVD events, termed subclinical atherosclerosis, include intima-media thickness and artery plaques and constitute a hallmark of atherosclerosis. These can be measured by ultrasonography and provide a surrogate endpoint of cardiovascular outcomes.
> View Complete Commentary <